Pharmacotherapy Choice Is Associated with 2-Year Mortality for Patients with Heart Failure and Reduced Ejection Fraction

ConclusionIPT was associated with decreased 2-year mortality risk. Timely consideration of triple IPT therapies may be warranted once HFrEF diagnosis is confirmed.FundingNovartis Pharmaceuticals Corp. located in East Hanover, NJ, USA.

Source: Advances in Therapy - October 10, 2017 Category: Drugs & Pharmacology Source Type: research